Skip to content
lifestyle.onlygolfnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Scynexis
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
October 6, 2026
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
September 28, 2026
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
September 22, 2026
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
September 15, 2026
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
September 10, 2026
SCYNEXIS to Participate in Upcoming Investor Conferences
September 1, 2026
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 30, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
May 22, 2026
1
2
Next Page
→